1223452-45-6

Basic information

• Product Name: 3,5-DiMethyl-isoxazole-4-carboxylic acid Methoxy-Methyl-aMide
• Synonyms: 3,5-DiMethyl-isoxazole-4-carboxylic acid Methoxy-Methyl-aMide;N-methoxy-N-methyl-3,5-dimethylisoxazole-4-carboxamide;N-METHOXY-N,3,5-TRIMETHYLISOXAZOLE-4-CARBOXAMIDE
• CAS NO: 1223452-45-6
• Molecular Formula: C₈H₁₂N₂O₃
• Molecular Weight: 184.19248
• Mol File: 1223452-45-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,5-DiMethyl-isoxazole-4-carboxylic acid Methoxy-Methyl-aMide(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DiMethyl-isoxazole-4-carboxylic acid Methoxy-Methyl-aMide(1223452-45-6)
• EPA Substance Registry System: 3,5-DiMethyl-isoxazole-4-carboxylic acid Methoxy-Methyl-aMide(1223452-45-6)

Safety Data

• Hazardous Substances Data: 1223452-45-6(Hazardous Substances Data)

Upstream product

• 31301-45-8 3,5-dimethylisoxazole-4-carbonyl chloride 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 2510-36-3 3,5-dimethyl-4-isoxazolecarboxylic acid 

Downstream Products

• 35166-20-2 1-(3,5-dimethyl-1,2-oxazol-4-yl)ethanone 
• 1616100-66-3 tert-butyl ((4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-yl)carbamate 
• 1616100-65-2 tert-butyl (4S,6S)-4-(5-bromo-2,4-difluorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-ylcarbamate 
• 1616100-64-1 (4S,6S)-4-(5-bromo-2,4-difluorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1585970-78-0 (R)-N-((S)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(3,5-dimethylisoxazol-4-yl)-4-oxobutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1585971-26-1 (R)-N-((S)-2-(5-bromo-2,4-difluorophenyl)-4-(3,5-dimethylisoxazol-4-yl)-4-oxobutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1585971-25-0 (R)-N-((2S,4R)-2-(5-bromo-2,4-difluorophenyl)-4-(3,5-dimethylisoxazol-4-yl)-4-hydroxybutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1585971-22-7 (1R,3S)-3-amino-3-(5-bromo-2,4-difluorophenyl)-1-(3,5-dimethylisoxazol-4-yl)butan-1-ol 
• 1616100-22-1 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-70-9 N-(((2S,4R)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(3,5-dimethylisoxazol-4-yl)-4-hydroxybutan-2-yl)carbamothioyl)benzamide 
• 1616100-69-6 (1R,3S)-3-amino-3-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-1-(3,5-dimethylisoxazol-4-yl)butan-1-ol 
• 1616100-68-5 (R)-N-((2S,4R)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(3,5-dimethylisoxazol-4-yl)-4-hydroxybutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1289207-41-5 4-(4-bromo-3-(4-methoxyphenyl)-5-methyl-1H-pyrrol-2-yl)-3,5-dimethylisoxazole 
• 1289207-40-4 4-(3-(4-methoxyphenyl)-5-methyl-1H-pyrrol-2-yl)-3,5-dimethylisoxazole 

Relevant articles and documents

Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors

Inhibition of transforming growth factor β (TGF-β) type 1 receptor (ALK5) provides a feasible approach for the treatment of fibrotic diseases and malignant tumors. In this study, we designed and synthesized a new series of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives, and evaluated biologically as TGF-β type 1 receptor inhibitors. The most potent compound 15r inhibited the ALK5 enzyme and NIH3T3 cell viability with IC50 values of 44 and 42.5 nM, respectively. Compound 15r also displayed better oral plasma exposure and excellent bioavailability than LY-3200882, and in vivo inhibited 65.7% of the tumor growth in a CT26 xenograft mouse model.

Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents

By targeting the flap backbone of the BACE1 active site, we discovered 6-dimethylisoxazole-substituted biaryl aminothiazine 18 with 34-fold improved BACE1 inhibitory activity over the lead compound 1. The cocrystal structure of 18 bound to the active site indicated two hydrogen-bond interactions between the dimethylisoxazole and threonine 72 and glutamine 73 of the flap. Incorporation of the dimethylisoxazole substitution onto the related aminothiazine carboxamide series led to pyrazine-carboxamide 26 as a very potent BACE1 inhibitor (IC50 1 nM). This compound demonstrated robust brain Aβ reduction in rat dose-response studies. Thus, compound 26 may be useful in testing the amyloid hypothesis of Alzheimer's disease.

Pyrimidinone Derivatives as Antimalarial Agents

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.

4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 al-kyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, halo C1-4 alkyl, CN, C1-C6, alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -SO2C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, ben-zyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z to-gether can be absent

PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n = 0 or 1 and R2 is a methyl group when n = 0 and a hydrogen atom when n = 1. Process for the preparation thereof and therapeutic use thereof.

SUBSTITUTED PYRROLES AND IMIDAZOLES AS ESTROGEN RECEPTOR LIGANDS

The invention provides a compound of formula (I) wherein G is a pyrrole or imidazole moiety and R4, R5, R6, R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.